Lonza and Vineti have agreed to become preferred partners in the cell and gene therapy field, for patient tissue tracking and for contract development and manufacturing services in cell and gene therapy, respectively.
The partnership comprises an integrated offering including logistics, scheduling, distribution, chain of condition, chain of custody, chain of identity, and Lonza's proprietary solutions such as MODA-ES.
For Lonza Pharma & Biotech, Alberto Santagostino, SVP Head of Cell & Gene Technologies, commented: “As our customers move towards commercialization with increasing patient population sizes, they need reliable, fast and efficient technologies and infrastructures to handle seamlessly the collection, process and delivery of their therapies. This is what we aim to achieve with this partnership.”
Supply chain platform
The Vineti supply chain orchestration (SCO) platform—an independent solution deemed to be the sole offer on the cell and gene therapy market—will help Lonza's customers to keep a real-time end-to-end connection between Lonza and the points of care that prescribe their therapies.
Ultimately, the Lonza-Vineti solution will seek to provide biopharmaceutical developers with a pre-integrated SCO and manufacturing system that will offer digital, optimised end-to-end traceability and control.
“We’re very honoured to have been selected as Lonza’s preferred supply chain orchestration partner,” said Amy DuRoss, CEO and Co-founder of Vineti. “Vineti and Lonza have a shared vision to grow, scale, and standardize the production and operations of cell and gene therapy worldwide. We’re very excited to serve biopharmaceutical partners together and to help open up patient access to these therapies more than ever before.”
